217 related articles for article (PubMed ID: 34600589)
1. Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry.
Amer M; Kamel AM; Bawazeer M; Maghrabi K; Butt A; Dahhan T; Kseibi E; Khurshid SM; Abujazar M; Alghunaim R; Rabee M; Abualkhair M; Al-Janoubi A; AlFirm AT; Gajic O; Walkey AJ; Mosier JM; Zabolotskikh IB; Gavidia OY; Teruel SY; Bernstein MA; Boman K; Kumar VK; Bansal V; Kashyap R;
Eur J Med Res; 2021 Oct; 26(1):117. PubMed ID: 34600589
[TBL] [Abstract][Full Text] [Related]
2. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
Gupta S; Wang W; Hayek SS; Chan L; Mathews KS; Melamed ML; Brenner SK; Leonberg-Yoo A; Schenck EJ; Radbel J; Reiser J; Bansal A; Srivastava A; Zhou Y; Finkel D; Green A; Mallappallil M; Faugno AJ; Zhang J; Velez JCQ; Shaefi S; Parikh CR; Charytan DM; Athavale AM; Friedman AN; Redfern RE; Short SAP; Correa S; Pokharel KK; Admon AJ; Donnelly JP; Gershengorn HB; Douin DJ; Semler MW; Hernán MA; Leaf DE;
JAMA Intern Med; 2021 Jan; 181(1):41-51. PubMed ID: 33080002
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
Hermine O; Mariette X; Tharaux PL; Resche-Rigon M; Porcher R; Ravaud P;
JAMA Intern Med; 2021 Jan; 181(1):32-40. PubMed ID: 33080017
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
; Gordon AC; Mouncey PR; Al-Beidh F; Rowan KM; Nichol AD; Arabi YM; Annane D; Beane A; van Bentum-Puijk W; Berry LR; Bhimani Z; Bonten MJM; Bradbury CA; Brunkhorst FM; Buzgau A; Cheng AC; Detry MA; Duffy EJ; Estcourt LJ; Fitzgerald M; Goossens H; Haniffa R; Higgins AM; Hills TE; Horvat CM; Lamontagne F; Lawler PR; Leavis HL; Linstrum KM; Litton E; Lorenzi E; Marshall JC; Mayr FB; McAuley DF; McGlothlin A; McGuinness SP; McVerry BJ; Montgomery SK; Morpeth SC; Murthy S; Orr K; Parke RL; Parker JC; Patanwala AE; Pettilä V; Rademaker E; Santos MS; Saunders CT; Seymour CW; Shankar-Hari M; Sligl WI; Turgeon AF; Turner AM; van de Veerdonk FL; Zarychanski R; Green C; Lewis RJ; Angus DC; McArthur CJ; Berry S; Webb SA; Derde LPG
N Engl J Med; 2021 Apr; 384(16):1491-1502. PubMed ID: 33631065
[TBL] [Abstract][Full Text] [Related]
7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for ventilator-associated lower respiratory tract infection in COVID-19, a retrospective multicenter cohort study in Sweden.
Forsberg G; Taxbro K; Elander L; Hanberger H; Berg S; Idh J; Berkius J; Ekman A; Hammarskjöld F; Niward K; Balkhed ÅÖ
Acta Anaesthesiol Scand; 2024 Feb; 68(2):226-235. PubMed ID: 37751991
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.
Estenssoro E; Loudet CI; Ríos FG; Kanoore Edul VS; Plotnikow G; Andrian M; Romero I; Piezny D; Bezzi M; Mandich V; Groer C; Torres S; Orlandi C; Rubatto Birri PN; Valenti MF; Cunto E; Sáenz MG; Tiribelli N; Aphalo V; Reina R; Dubin A;
Lancet Respir Med; 2021 Sep; 9(9):989-998. PubMed ID: 34224674
[TBL] [Abstract][Full Text] [Related]
10. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lescure FX; Honda H; Fowler RA; Lazar JS; Shi G; Wung P; Patel N; Hagino O;
Lancet Respir Med; 2021 May; 9(5):522-532. PubMed ID: 33676590
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
12. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L; Chaimani A; Evrenoglou T; Davidson M; Graña C; Schmucker C; Bollig C; Henschke N; Sguassero Y; Nejstgaard CH; Menon S; Nguyen TV; Ferrand G; Kapp P; Riveros C; Ávila C; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Boutron I
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013881. PubMed ID: 33734435
[TBL] [Abstract][Full Text] [Related]
15. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
[TBL] [Abstract][Full Text] [Related]
16. Systemic corticosteroids for the treatment of COVID-19.
Wagner C; Griesel M; Mikolajewska A; Mueller A; Nothacker M; Kley K; Metzendorf MI; Fischer AL; Kopp M; Stegemann M; Skoetz N; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014963. PubMed ID: 34396514
[TBL] [Abstract][Full Text] [Related]
17. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
20. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
